Bellerophon Therapeutics, Inc.
Bellerophon Therapeutics, Inc. (BLPH): 1 pipeline candidate · ~2 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
2.2 months
D/E 0.34 · 0% dilution
Lead: Phase 2
1 candidate
N/A
N/A
A transparent, data-derived signal for Bellerophon Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$4.4M
Quarterly Burn
$6.3M
Runway
2.2 mo
Revenue
$0
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (1 candidate)
| Drug | Phase |
|---|---|
| inopulse | Phase 2 |
Frequently asked questions
How many drug candidates are in Bellerophon Therapeutics, Inc.'s pipeline?
Bellerophon Therapeutics, Inc. (BLPH) has 1 pipeline candidate tracked by BioSniper across SEC filings and clinical trial registrations.
What is Bellerophon Therapeutics, Inc.'s lead drug candidate?
Bellerophon Therapeutics, Inc.'s most advanced tracked candidate is inopulse (Phase 2) for Pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD).
What is Bellerophon Therapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Bellerophon Therapeutics, Inc. has approximately 2.2 months of cash runway.
Who is the CEO of Bellerophon Therapeutics, Inc.?
To Be Held is the chief executive officer of Bellerophon Therapeutics, Inc. (BLPH).
Get the full picture on Bellerophon Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.